Iovance Biotherapeutics logo

Iovance Biotherapeutics

IOVA | NASDAQ
Chart Builder DCF Calculator
$7.55
-$0.21 (-2.71%)
At close: Nov 16, 2026, 4:00 PM ET
$7.48
-$0.07 (-0.93%)
After-hours: Nov 16, 2026, 7:59 PM ET
-2.71%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 14, 2026
54.5
Fundamentals Strong
Market Sentiment Neutral
Moat Narrow
Sector Rank #196/1021 (Top 19%)

Key Statistics

Market Data

Market Cap $3.49B
1D Range
7.50 7.84
52W Range
2.13 14.86

Valuation (TTM)

PE -14.25
PB 4.30
EV/EBITDA -17.08

Valuation (NTM)

Forward PE N/A
Forward PEG 0.23
Price Target $15.00
Loading financial charts...

Profile

Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical development stage, is committed to discovering and bringing to market cancer immunotherapy solutions. Its core mission inv...

Sector Healthcare
Industry Biotechnology
Employees 975
IPO Date Oct 15, 2010
Fiscal Year January - December

Latest News

Iovance Biotherapeutics Targets 2027 Lung Cancer Filing as AMTAGVI Sales Climb

16 hours ago · marketbeat.com

Iovance Biotherapeutics Targets 2027 Lung Cancer Filing as AMTAGVI Sales Climb
Iovance: The Lung Selloff Went Too Far For A Business Growing 77%

23 hours ago · seekingalpha.com

Iovance: The Lung Selloff Went Too Far For A Business Growing 77%
Iovance Biotherapeutics to Present at Upcoming Conference

4 days ago · globenewswire.com

Iovance Biotherapeutics to Present at Upcoming Conference
IOVA Q3 Earnings Beat on Amtagvi Sales and Lower R&D Costs

11 days ago · zacks.com

IOVA Q3 Earnings Beat on Amtagvi Sales and Lower R&D Costs
Iovance Q3 Earnings: Why I'm Reiterating My Buy Call Despite Market Reaction

11 days ago · seekingalpha.com

Iovance Q3 Earnings: Why I'm Reiterating My Buy Call Despite Market Reaction
Iovance: Reset Expectations Make The Stock A Buy Again (Rating Upgrade)

11 days ago · seekingalpha.com

Iovance: Reset Expectations Make The Stock A Buy Again (Rating Upgrade)
IOVA Q3 Earnings Call Highlights Amtagvi Growth and Pipeline Progress

11 days ago · zacks.com

IOVA Q3 Earnings Call Highlights Amtagvi Growth and Pipeline Progress
Iovance Biotherapeutics, Inc. (IOVA) Q3 2026 Earnings Call Transcript

11 days ago · seekingalpha.com

Iovance Biotherapeutics, Inc. (IOVA) Q3 2026 Earnings Call Transcript
Iovance Biotherapeutics Q3 Earnings Call Highlights

11 days ago · marketbeat.com

Iovance Biotherapeutics Q3 Earnings Call Highlights
Iovance Biotherapeutics (IOVA) Reports Q3 Loss, Beats Revenue Estimates

12 days ago · zacks.com

Iovance Biotherapeutics (IOVA) Reports Q3 Loss, Beats Revenue Estimates

Earnings

Latest Earnings
Nov 5, 2026
EPS
-$0.05
Beat +40.54%
REV
$121.47M
Beat +4.73%
Next Earnings
Feb 23, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
9
Consensus
Buy
Price Target
$15.00
Upside
+98.68%
Buy (7)
Hold (2)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.